Navigation Links
Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference
Date:8/3/2010

EMERYVILLE, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 10, 2010 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).

Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through August 24, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
(Date:5/4/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... announced that it is teaming up with Auto Control ... lower diabetes healthcare costs in Canada ... available throughout all provinces and territories in ... additional savings when shopping for Dario supplies in local ...
(Date:5/3/2017)... ORANGE COUNTY, Calif. , May 3, 2017 ... vital aspect of any hospital or healthcare facility. ... of examination room is equipped with diagnostic imaging ... and arteries of the heart. In these spaces, ... coronary angiography, catheterization, balloon angioplasty, percutaneous coronary intervention, ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For Solutions has ... ART laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools ... MedTech Group Purchasing vendor , will provide specialized equipment to ensure OvaTools ...
(Date:5/23/2017)... ... May 23, 2017 , ... Orbita’s Nathan Treloar will discuss ... 2017 in San Francisco. Titled Connected Health and IoT: Technology Innovators and Disruption ... hosted by Parks Associates, a market research and consulting firm specializing in emerging consumer ...
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... Mt. Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced ... can be administered for a variety of treatments. One or more sedation methods may ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., wants to offer ... hand was damaged in a firework accident, so she couldn’t grip a pen properly," ... , He then designed and created a prototype for the HELPEN HAND, a special ...
Breaking Medicine News(10 mins):